<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538239</url>
  </required_header>
  <id_info>
    <org_study_id>8669-011</org_study_id>
    <secondary_id>AP23573-07-302</secondary_id>
    <nct_id>NCT00538239</nct_id>
  </id_info>
  <brief_title>Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)</brief_title>
  <acronym>SUCCEED</acronym>
  <official_title>A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether maintenance therapy with oral AP23573
      (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in
      patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result
      in clinically significant improvement in progression-free survival as compared to oral
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 157 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival: First Analysis</measure>
    <time_frame>Up to 157 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Target Lesion Response (RECIST)</measure>
    <time_frame>Up to 157 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Updated Analysis as of 30 April 2011</measure>
    <time_frame>Up to 184 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Updated Analysis as of 21 January 2012</measure>
    <time_frame>Up to 222 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 157 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">711</enrollment>
  <condition>Metastatic Soft-Tissue Sarcomas</condition>
  <condition>Metastatic Bone Sarcomas</condition>
  <arm_group>
    <arm_group_label>Ridaforolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ridaforolimus</intervention_name>
    <description>Four 10 mg tablets taken by mouth for 5 days per week continuously</description>
    <arm_group_label>Ridaforolimus</arm_group_label>
    <other_name>deforolimus</other_name>
    <other_name>AP23573</other_name>
    <other_name>MK-8669</other_name>
    <other_name>ridaforolimus was also known as deforolimus until May 2009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four 10 mg tablets taken by mouth for 5 days per week continuously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of metastatic soft-tissue or bone sarcoma

          -  Ongoing complete response, partial response, or stable disease (RECIST) after a
             minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third line
             of prior cytotoxic chemotherapy for metastatic disease

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Adequate organ and bone marrow function

          -  Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks
             prior to randomization

        Exclusion Criteria:

          -  Prior therapy with rapamycin or rapamycin analogs

          -  Ongoing toxicity associated with prior anticancer therapy

          -  Another primary malignancy within the past three years

          -  Concomitant medications that induce or inhibit CYP3A

          -  Significant, uncontrolled cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.ariad.com/wt/tertiarypage/succeed_trial</url>
  </link>
  <results_reference>
    <citation>Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28.</citation>
    <PMID>23715582</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

